Controlled clinical trial of levamisole in short-course chemotherapy for pulmonary tuberculosis. A Kenyan/Zambian/British Medical Research Council Collaborative Study

The American Review of Respiratory Disease

Abstract

The effect of adding a once-weekly dose of levamisole for 4 or 8 wk to a 6-month antituberculosis chemotherapy regimen has been studied in a double-blind, placebo-controlled clinical trial. All patients received the same daily chemotherapy regimen of streptomycin, isoniazid, rifampin, and pyrazinamide for 8 wk followed by thiacetazone and isoniazid for 18 wk, the first 10 wk being given fully supervised on an inpatient basis in hospital and the remainder to be self-administered at home. In 504 patients with fully susceptible strains pretreatment assessed at the end of chemotherapy, there was no evidence of an advantage to the patients receiving levamisole for 8 wk (L8 series) or 4 wk (L4 series) when compared with those receiving placebo only (L0 series) in terms of the rate of achievement of sputum culture negativity or of radiographic improvement at independent assessment. The bacteriologic relapse rates in 2 yr of follow-up were also similar in the three series, namely, 8% for the 144 patients in the L8, 5% for the 152 in the L4, and 8% for the 160 in the L0 series. There was thus no evidence of benefit from levamisole in the dosage schedule studied. The frequency of adverse reactions to the antituberculosis drugs was unaffe...Continue Reading

Citations

Jan 1, 1996·The Psychiatric Quarterly·E SusserN Sohler
Mar 1, 1986·Indian Journal of Pediatrics·V Seth
Aug 1, 1994·International Journal of Antimicrobial Agents·V St Georgiev
May 31, 2008·American Journal of Respiratory and Critical Care Medicine·Anton MakDick Menzies
Feb 1, 1994·Tubercle and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·J Dhillon, D A Mitchison

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.